Skip to main content

Table 4 Mean scores of criterions of five DPP-4 inhibitors

From: Impact on decision making framework for medicine purchasing in Chinese public hospital decision-making: determining the value of five dipeptidyl peptidase 4 (DPP-4) inhibitors

 

Saxagliptin

Alogliptin

Sitagliptin

linagliptin

Vildagliptin

 

Mean

SD

Mean

SD

Mean

SD

Mean

SD

Mean

SD

Disease severity

4.00

1.26

4.00

1.26

4.00

1.26

4.00

1.26

4.00

1.26

Size of affected population

4.33

0.52

4.33

0.52

4.33

0.52

4.33

0.52

4.33

0.52

Unmet needs

3.50

0.55

3.50

0.55

3.50

0.55

3.50

0.55

3.50

0.55

Comparative effectiveness

3.50

1.64

4.33

1.03

4.67

0.52

4.33

1.03

3.67

1.51

Comparative safety/tolerability

0.17

0.98

0.33

0.82

0.83

0.75

0.67

1.21

0.67

0.82

Comparative patient-perceived health / PRO

-0.17

0.41

-0.33

0.52

-0.17

0.41

-0.17

0.41

-0.50

0.55

Type of therapeutic benefit

4.00

0.00

4.00

0.00

4.00

0.00

4.00

0.00

4.00

0.00

Type of preventive benefit

/

/

/

/

/

/

/

/

/

/

Comparative cost consequences – cost of intervention

-1.83

1.33

-1.83

1.33

-1.50

0.84

-1.33

0.82

-1.17

0.98

Comparative cost consequences – other medical costs

/

/

/

/

/

/

/

/

/

/

Comparative cost consequences – non-medical costs

-1.83

1.47

-1.67

1.51

-1.33

1.03

-1.50

1.05

-1.33

1.21

Quality of evidence

3.33

0.82

3.33

0.82

3.33

0.82

3.33

0.82

3.33

0.82

Expert consensus/clinical practice guidelines

3.67

1.51

3.67

1.51

3.67

1.51

3.67

1.51

3.67

1.51